5542-60-9

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(4-CHLOROPHENOXY)-2-METHYLPROPANOYL CHLORIDE is used as a key intermediate for the production of various pharmaceuticals. Its strong acylating properties allow for the modification of organic molecules, contributing to the development of new drug compounds.
Used in Agrochemical Production:
In the agrochemical industry, 2-(4-CHLOROPHENOXY)-2-METHYLPROPANOYL CHLORIDE is utilized in the production of herbicides and pesticides. Its reactivity enables the creation of effective compounds for controlling weeds and pests in agricultural settings.
Used in Research and Development:
2-(4-CHLOROPHENOXY)-2-METHYLPROPANOYL CHLORIDE is employed in research and development due to its versatile reactivity. It serves as a valuable tool for scientists to explore new chemical reactions and synthesize novel compounds with potential applications in various fields.

Upstream product

• 882-09-7 Clofibric acid 
• 1193-00-6 sodium 4-chlorophenolate 
• 96-36-6 methyl phosphite 
• 111-92-2 dibutylamine 
• 81928-53-2 dimethyl p-chlorophenoxyisobutyrylphosphonate 
• 106-48-9 4-chloro-phenol 

Downstream Products

• 56532-11-7 α-(4-chloro-phenoxy)-isobutyric acid propyl ester 
• 146699-49-2 α-(4-chloro-phenoxy)-isobutyric acid octyl ester 
• 146699-50-5 α-(4-chloro-phenoxy)-isobutyric acid dodecyl ester 
• 637-07-0 Clofibrate 
• 5658-61-7 2-(4-chlorophenoxy)-2-methylpropanamide 
• 55162-41-9 2-[4-chlorophenoxy]-2-methylpropionic acid methyl ester 
• 61887-16-9 dulofibrate 
• 62753-35-9 α-(4-chloro-phenoxy)-isobutyric acid allyl ester 
• 128965-91-3 α-(4-chloro-phenoxy)-isobutyric acid methylamide 
• 112551-43-6 (+/-)-α-(4-chloro-phenoxy)-isobutyric acid-(1,2t,5c-trimethyl-4-phenyl-[4r]piperidyl ester) 
• 54405-21-9 α-(4-chloro-phenoxy)-isobutyric acid butyl ester 
• 93017-56-2 2-(4-chloro-phenoxy)-2-methyl-propionic acid 2-morpholin-4-yl-2-oxo-ethyl ester 
• 65568-95-8 4-[2-(4-chlorphenoxy)isobutyroylamino]-5-chloro-2-methoxy-N-[2-(diethylamino)-ethyl]benzamide 
• 64401-09-8 (S)-3-[2-(4-chloro-phenoxy)-2-methyl-propionyl]-2,2,5,5-tetramethyl-thiazolidine-4-carboxylic acid 

Relevant academic research and scientific papers

The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions

Multi-action cisplatin-based mono- (1) and di-clofibric acid (2) Pt(iv) "combo" derivatives were synthesized via both traditional and microwave assisted procedures. The two complexes offered very good performances (IC50 values in a nanomolar ra

The formation of benzoxacin-3-ones: Via intramolecular Nicholas reactions and synthesis of 8-membered heliannuols

The γ-carbonyl cations generated from propargyl ether-Co2(CO)6 complexes undergo intramolecular Nicholas reactions to give dehydrobenzoxacin-3-one-Co2(CO)6 complexes in good yields. Reductive decomplexation and subsequent manipulation allows the synthesis of (±)-heliannuol K methyl ether and the formal syntheses of (±)-heliannuol K, (±)-heliannuol A, and (-)-heliannuol L.

Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I

Activation of AMPK emerges as a potential therapeutic approach to metabolic diseases. AdipoRon is claimed to be an adiponectin receptor agonist that activates AMPK through adiponectin receptor 1 (AdipoR1). However, AdipoRon also exhibits moderate inhibition of mitochondrial complex I, leading to increased risk of lactic acidosis. In order to find novel AdipoRon analogues that activate AMPK without inhibition of complex I, 27 analogues of AdipoRon were designed, synthesized and biologically evaluated. As results, benzyloxy arylamide B10 was identified as a potent AMPK activator without inhibition of complex I. B10 dose-dependently improved glucose tolerance in normal mice, and significantly lowered fasting blood glucose level and ameliorated insulin resistance in db/db diabetic mice. More importantly, unlike the pan-AMPK activator MK-8722, B10 did not cause cardiac hypertrophy, probably owing to its selective activation of AMPK in the muscle tissue but not in the heart tissue. Together, B10 represents a novel class of AMPK activators with promising therapeutic potential against metabolic disease.

Diester compounds of PPAR protein activator

The invention relates to diester compounds of a PPAR protein activator. The compounds are compounds shown in the formula (I) and pharmaceutically acceptable salts, prodrugs and solvates thereof, and apharmaceutical composition comprising the compounds and a synthesis method thereof. Furthermore, the invention relates to pharmaceutical composition comprising the compounds, and the pharmaceutical composition can be used for the prevention or treatment on diseases associated with PPPAR proteins.

Acetophenone compounds, preparation methods thereof and application thereof in regulating blood lipid

The invention discloses a compound as shown in formula I or pharmaceutically acceptable salt and a preparation method thereof as well as application thereof in the preparation of drugs for regulatingblood lipid.

Pd(II)-catalyzed ortho - Or meta-C-H olefination of phenol derivatives

A combination of weakly coordinating auxiliaries and ligand acceleration allows for the development of both ortho- and meta-selective C-H olefination of phenol derivatives. These reactions demonstrate the feasibility of directing C-H functionalizations when functional groups are distal to target C-H bonds. The meta-C-H functionalization of electron-rich phenol derivatives is unprecedented and orthogonal to previous electrophilic substitution of phenols in terms of regioselectivity. These methods are also applied to functionalize α-phenoxyacetic acids, a fibrate class of drug scaffolds.

N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

AMINE AND ETHER COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR

Compounds which modulate the CB2 receptor are disclosed. The compounds are useful for treating CB2 receptor-mediated diseases such as pain.

Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity

The discovery of novel acyclic amide cannabinoid-1 receptor inverse agonists is described. They are potent, selective, orally bioavailable, and active in rodent models of food intake and body weight reduction. A major focus of the optimization process was to increase in vivo efficacy and to reduce the potential for formation of reactive metabolites. These efforts led to the identification of compound 48 for development as a clinical candidate for the treatment of obesity.

SUBSTITUTED AMIDES ACTIVE AT THE CANNABINOID-1 RECEPTOR

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.